secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001493152-24-019117
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed reports Q1 2024 net loss of $22.8M; EsoGuard revenue flat QoQ at $1.0M
-----------------------------------------------------------------------------

- GAAP net loss $22.8M ($2.62 per share); non-GAAP adjusted loss $8.6M ($0.99 per share).
- EsoGuard revenue $1.0M (flat vs Q4 2023, +124% YoY); operating expenses $15.0M.
- Lucid completed $29.8M Series B Preferred Stock offering to strengthen balance sheet.
- Secured July 17, 2024 MolDX pre-submission meeting for technical assessment under LCD.
- Veris Health completed MOU with Ohio State's James Cancer Hospital for pilot program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315224019117/0001493152-24-019117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315224019117/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer